ABVX News

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Focus on French HealthTech’s ecosystem : Panorama France HealthTech 2026 ‘s review: a mature, innovative and resilient sector facing a more demanding environment

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies